金吾财讯 | 据港交所10月31日披露，脑动极光医疗科技通过港交所上市聆讯，中金公司、浦银国际为联席保荐人。公司成立于2012年，公司产品管线涵盖由血管疾病、神经退行性疾病、精神疾病及儿童发育缺陷等诱发的广泛的认知障碍的测评和干预。财务方面，公司于2021年、2022年及2023年以及截至2023年及2024年6月30日止六个月，收入分别为229.9万、1129.1万、6720万、2441.2万及5188.7万人民币；公司拥有人应占亏损分别为6.98亿、5.02亿、3.59亿、2.35亿及1.14亿元人民币。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.